Robots Predicted to be Performing 85% of surgeries by 2025
Momentum Public Relations
Blog: July 11, 2018
AI Medical Diagnosis APP Gets Better Exam Mark Than Doctors
Exploding AI Medical Market Predicted to Hit US$12.15 Billion by 2023
Robots Predicted to be Performing 85% of surgeries by 2025
On June 28, 2018, Forbes ran a story with the headline reading, “This AI Just Beat Human Doctors on a Clinical Exam MD.”
The story by Parmy Olson, tells how an artificial intelligence application created by Babylon Health scored on a standard British test designed to grade the diagnostic ability of doctors in training. For the last five years the average passing grade has been 72%. Babylon Health’s artificial intelligence powered software performed ten points above the average coming in at 82%.
At the beginning of 2018 Research House Frost & Sullivan made some predictions. The one that perhaps best defines future shock is that by 2025, 85% of surgical procedures are likely to be done by robots. Over the next two to three years Frost & Sullivan also predict that AI platforms in medical imaging will increase productivity by 10-15%.
Babylon Health was founded five years ago and has raised US$85 million for research and development. Babylon has developed an intriguing mix of AI and human diagnosis that could if adopted drive down overall health care costs by using its diagnostic apps to pre-screen patients and suggest what’s wrong, while leaving the final diagnosis in the hands of a living breathing MD.
While at first this may seem like an episode of Star Trek, the service is real enough. The company’s largest and most important client to date is the British National Health Service which has allowed 26 thousand patients to transfer from the standard GP based service to Babylon. Another 20,000 are on a waiting list.
In a typical scenario a Babylon patient will describe symptoms to a diagnostic engine which will then suggest a probable diagnosis. Then there is the video call between doctor and patient. While the interview is going on the app automatically records and transcribes the interview. The patients face is analyzed to determine if he or she is feeling confused, worried or normal, according to the movements of 117 muscles located in the nose, lips or eyebrows. At the end of the consultation the live doctor will, if necessary send a prescription to the patients pharmacy.
The software also creates a digital twin of the patient and the company believes the twin will be used to determine what medical problems will develop in the future. All of this should help make healthcare timelier and more affordable.
Babylon’s business model is to sell its services to health care providers such as government Medicare systems or health insurance companies. The company also sells its consulting service to individuals and offers access to software that individuals can use to investigate an ailment. Babylon intends to launch in the US, during 2019.
Forbes sums up recent market activity like this, “Investment in the AI medical market is pouring in, from tech giants like IBM’s Watson, Alphabet and Philips to pharmaceutical companies and swiftly proliferating start-ups. The market for artificial intelligence in health care and the life sciences is projected to grow by 40 percent a year, to $6.6 billion in 2021, according to estimates from Frost & Sullivan.”
In March of this year research house Mordor Intelligence predicted that by 2023 the global artificial intelligence in medicine market would reach US$ 12.15 Billion. The report, Artificial Intelligence in Medicine Market-by Application and Geography-Growth, Trends, and forecasts (2018-2023) details how AI is moving into the medical workplace providing faster and more efficient medical care.
While AI can be used to manage patient records and other types of data the real payoff for AI in medical applications comes in reducing human error. When AI systems have been used in image labelling, error rates have been reduced from 28.5% to 2.5%.
According to Mordor, the artificial intelligence in medicine market will grow from US$1.6 billion in 2017 to US$12.5 billion by 2023, a CAGR of 40.15% from 2018 to 2023. A number of factors are driving the market and can be divided into two categories. On the one hand there is the increased efficiency which AI systems offer providing a more efficient diagnosis. This also applies to patient data management. Both of these, better diagnosis and better data management, will help drive down the cost of medical treatment.
The flip side of the coin is the high cost of error. According to the Mordor report preventable medical mistakes result in roughly 210,000 deaths per year. Diagnostic mistakes account for roughly 440,000 deaths per year. And finally, medical mistakes cost the healthcare industry approximately US$1 trillion per year.
As well as the companies listed above other key players developing artificial intelligence and deep learning medical applications include: Intel; Microsoft, Siemens and General Electric.
With a market value that is growing at 40% CAGR a year, the AI in medical applications market is a developing sector that retail investors should take a good look at. It is a market driven by demographic factors, as the baby boomers continue to age they will require more medical attention, and efficiency. Any technology that cuts medical costs will be highly valued.
While there are no sure bets in the stock market, one AI diagnosis company that you should take a look at is the Montreal-based Diagnos. Diagnos has specialized in developing a proprietary technology, CARA, computer assisted retinal analysis that uses enhanced retinal digital images to detect the initial stages of diabetic retinopathy.
The retina is at the back of the eye and it is the only place where doctors can observe veins and arteries and detect early diabetes. Diabetes can lead to blindness if untreated and early detection can prevent 85-90% of vision loss. The process is simple. An image of the eye is taken and then image can then be analyzed.
CARA has been used to diagnose 222,034 patients at last count, in 16 countries, using 131 screening sites. In early June, The Montreal Gazette ran a story on Diagnos’ setting up its first Canadian pilot project at the Centre hospitalier de l’Universite de Montreal (CHUM). Diagnos is a company on the move and with its shares, (TSXV: ADK) closing at $0.06 on July 10, 2018, an attractive entry point into the explosive AI medical market.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FULL DISCLOSURE: Diagnos is a paid client of Momentum PR.
- Published in Blog
Relevium Selects 93,000 Sq. Ft Organic Cultivation Facility in Quebec
Momentum Public Relations
Press Release: June 4 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that, through its wholly-owned subsidiary Biocannabix (“BCX”), it has selected a 93,000 square foot facility in Montreal, Quebec with the objective of cultivating premium organic cannabis.
With the assistance of PipeDreemz Inc., Relevium has conducted initial assessment on the facility, a 93,000 Sq. Ft industrial building located adjacent to the TransCanada Highway, Trudeau International Airport and about 20 minutes from downtown Montreal. The building has been selected as a desirable location with a low risk profile for the application submission to Health Canada for an ACMPR cultivation license. Biocannabix will be leveraging the vast experience of lead consultant George Routhier and his company PipeDreemz Inc., a company with a remarkable 100% rate of success with ACMPR licensing from Health Canada.
Company Strategy
The strategy for the Company is to cultivate high quality organic strains for use in exclusive, high-end consumer packaged goods primarily for health and wellness. The Company will not compete on large scale supply, but rather plans to focus on custom niche and organic products with established partnerships for processing and ongoing research in cannabis derivatives.
The Company intends to develop the project in stages and expects to retrofit the building with an initial phase of 10,000 Sq. Ft of cultivation. Upon the completion of the first stage, successful operations and licensing, the company will then proceed with phases 2 and 3. Construction of the project is subject to financing and customary approvals.
Aurelio Useche, CEO of Relevium stated: “The strategy of Biocannabix will not be catered around being the lowest cost producer, but rather on being a premium and custom producer focused on consumer packaged goods to be sold through Relevium’s current and new brands.” Mr. Useche stated further: “The value in the supply chain will be in developing trusted, unique, ultra-premium product for luxurious brands.”
About PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces Revenue of $3.2M for the Nine-Month Period Ended March 31, 2018
Momentum Public Relations
Press Release: May 30 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”) is pleased to announce its financial and operating results for the three and nine months’ period ended March 31, 2018.
Highlights
- Nine-month sales totalled $3,157,644 including Q3 sales of $1,063,176 recorded by Bioganix®
- Nine-month gross profit of $1,806,515 (57%), including Q2 gross profit of $575,495 (56%)
- In this reporting period, the Company:
- Initiated a market test for the eventual launch of a complete Aloe Vera based health support products and cosmetics
- Revealed a new brand architecture for Bioganix®
- Conducted the initial joint-launch of Planet Hemp with HEMPCO
- Established its presence for the European marketplace in partnership with Amazon
- The Company increased product offerings by 17% to 38 products with further plans to expand to over 50 products in 2018
Results from Operations
During the nine-month period ended March 31, 2018, the Bioganix brand generated $3,157,644 in sales revenues with a gross profit of $1,806,515. A gross margin of 57% continues to remain stable and adjusted EBITDA for the brand remains positive at 25%. On a consolidated basis, the Company reported an increase in expenses in three key areas:
- Selling and Marketing Expenses: The reporting period was marked by a period of preparation for market expansion, which included increased expenses relating to initiatives to build brand equity, expand geographically, launch of new products and build the operating team. The investments included brand repositioning and branding services, promotions and new product launches, increased digital marketing campaigns and other value-added services. The total marketing expense for the nine-month was reported at $1,252,668 with $313,167 allocated to market expansion, branding and product launch initiatives.
- Interest and Accretion Expenses: The Company reported a total of $612,040 ($348,422 of interest and $263,618 of accretion) in the nine-month reporting period for servicing the long-term convertible debt currently on the balance sheet.
- Share-based compensation: The Company reported $554,110 non-cash share-based compensation, reflecting stock options issued to directors, consultants and management in the reporting nine-month period.
These three key areas represent $2,418,818 or 67% of all the Company’s operating expenses for the nine-month reporting period. The Company reported net and comprehensive losses of $1,787,985 ($566,070 in 2017) and Adjusted Earnings Before Interest, Taxes and Amortization totaling $384,151 in the same period.
Aurelio Useche, President and CEO of Relevium stated: “We have increased our marketing and sales spend significantly to successfully launch a new brand, new products and to expand into new markets as previously announced.” Mr. Useche stated further: “Revenues from the original Bioganix product line remain as expected and believe that the additional investments will bear fruit once our presence in Amazon UK and Walmart.com is strong and the new products have taken hold within our customer base.”
For more information, the Company’s previous filings may be reviewed by visiting www.sedar.com and also our website www.releviumtechnologies.com.
Adjusted EBITDA and Non-IFRS Financial Measures
The Management Discussion and Analysis for the same period includes certain measures which are not defined terms in accordance with IFRS such as Adjusted EBITDA. The term “Adjusted EBITDA” refers to net income or net loss after adjusting for interest, taxes, depreciation and costs relating to acquisitions and their integration.
The Company believes that Adjusted EBITDA is useful, supplemental information as it provides an indication of the results generated by the company’s main business activities prior to taking into consideration how those activities are financed and taxed and prior to taking into consideration depreciation and particularly the costs of integration of acquisitions.
Adjusted EBITDA is also a key measure used by the Company’s management and its Board of Directors to understand and evaluate the Company’s operating performance, to prepare annual budgets, and to help develop operating plans. Adjusted EBITDA is not a measure of performance under IFRS and should not be considered in isolation or as a substitute for net and comprehensive income or loss prepared in accordance with IFRS or as a measure of operating performance or profitability.
Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
See “Adjusted EBITDA and Non-IFRS Financial Measures”
- Published in Relevium Technologies
Relevium Launches Bioganix® on Walmart.com
Momentum Public Relations
Press Release: May 3 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that it has received approval to sell its biggest mover Bioganix® products on Walmart.com.
Highlights
- New and diverse revenue channel with over 400M monthly visitors
- Onboarding and approval to Walmart.com is complete
- Sales testing of Bioganix® products is currently online
- Bioganix® will launch best selling SKUs and customize a new offering for a new demographic
- Opens a new sales vertical and mitigates channel risk
Walmart.com will provide Relevium with access to 400M new visitors per month with a diverse customer demographic and profile. According to CBS MoneyWatch, Walmart.com shoppers are primarily young women and nearly half have families with kids and a diverse ethnic profile. Amazon and Walmart demographics are complementary thereby mitigating channel risk for the Bioganix® brand.
Aurelio Useche, CEO of Relevium stated: “The addition of the Walmart.com platform to the existing Amazon.com sales channel gives Bioganix® a new and diverse audience and should prove to be accretive to revenues going forward.” Mr. Useche continued: “Diversifying our sales channels also de-risks the reliance on individual marketplaces and allows us to reach new customers across the USA, Europe and Asia. This is a major step for the Company and our expectations are high.”
Abis Hussain, SMO of Relevium, stated: “The Operations Team has concluded that the audience and the competition on Walmart.com is very different than those in Amazon.com and should reflect nicely on the bottom line for the Company. As an added bonus, Walmart.com will be key to the introduction of full spectrum hemp oil products, which will prove to be extremely valuable going forward as we prepare to launch products related to the space.”
Bioganix® products have been available on the Walmart.com platform, on a test-basis, for sale and delivery in the United States of America as of May 1, 2018. Initially, the Company will be offering five (5) to eight (8) of its best-selling products on the platform and then evaluate which products will subsequently be made available.
Relevium has the intention of selling products from its current catalogue as well as new products that will be launched in 2018. New products will be centered around major themes in the health and wellness markets including weight management, sports performance, ketogenic diets and general well being offered through hemp-derived products.
Bioganix® products will now be widely available in the USA through Bioganix.com, Amazon.com and Walmart.com and imminently in the United Kingdom through Amazon.co.uk.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces Agreement with Neptune Wellness for MaxSimil®
Momentum Public Relations
Press Release: April 30, 2019
Relevium Technologies Inc. (TSX.V:RLV), (OTCQB:RLLVF) and (Frankfurt:6BX) (the“Company” or “Relevium”), is pleased to announce the signing of a product development, supply and commercialization agreement with Neptune Wellness Solutions (TSX:NEPT) (NASDAQ:NEPT) for MaxSimil®, a patented fish oil monoglyceride omega 3 technology.
Highlights
- MaxSimil® is a technology that enhances the absorption of lipid and lipid-soluble ingredients in the production of nutraceuticals
- The agreement includes product development, supply and commercialization for Canada and USA
- Initial 2-year term
- Development of two (2) products in year one and an additional six (6) within year two
- The agreement includes Research and Development contribution by Relevium in the form of a 2.5% royalty on net sales payable to Neptune quarterly
Aurelio Useche, Relevium’s CEO “We are very pleased to partner with Neptune Wellness to develop new formulations combining MaxSimil® technology with plant derivatives and other nutraceutical ingredients, which will form part of current and future exclusive science-based brands” Mr. Useche continued: “The MaxSimil technology could prove to be a real differentiator for products marketed through our subsidiaries BGX Health and Biocannabix Health and their brands”
Francois-Karl Brouillette, Neptune’s VP, Science and Innovation stated:” Relevium’s business and product development strategies will be great accelerators to Neptune’s own MaxSimil® nutraceutical development program. Free of any unwanted excipients and mimicking our natural biological system, MaxSimil technology is an efficient nutraceutical-type delivery system that is perfectly compatible with today’s dietary supplement industry.” Mr. Brouillette added: “I strongly believe that this exciting new partnership will help us further unlock this patented technology’s full potential while extending its reach to a broader consumer base.”
About MaxSimil®
MaxSimil is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals. MaxSimil mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as plant and fish derived oils.
About Neptune Wellness Solutions
Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company formulates and provides turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products. The Company’s head office is located in Laval, Quebec.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses and entrepreneurial brands in the growing health and wellness sector. The Company creates value by building brand equity, organic product offering and geographic expansion. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook, Follow us on Twitter
and Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Creates Biocannabix Subsidiary and Targets Legal Cannabis Business
Momentum Public Relations
Press Release: April 19 2018
Relevium TechnologiesInc. (TSX VENTURE:RLV) (OTCQB:RLLVF) (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of Biocannabix Health Corporation (the “Subsidiary” or “BHC”), a Canadian wholly owned subsidiary structured to lead the development of the legal cannabis derivatives business for RLV. The Company projects to complete its ACMPR application for the Canadian marketplace within the current fiscal quarter and has begun to assemble its legal and regulatory team of experts within targeted jurisdictions.
Highlights
- Biocannabix Health Corporation to lead the Company’s legal cannabis initiatives
- Focus on developing a portfolio of high end consumer brands for North America
- Prepare for a global online marketplace for jurisdictions with a legal context
- Subsidiary anticipates applying for the necessary ACMPR licenses from Health Canada
- Initial commercial focus will be on industrial hemp derivatives such as CBG and CBD
As a Canadian company, Relevium will initially target the legal cannabinoids markets in North-America and develop medical, lifestyle and luxury consumer products aimed at supporting overall health and wellness. The Company’s newly created subsidiary is expected to begin the process of obtaining access to cannabis for medical purposes through the filing of an application for the appropriate licences from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The primary purpose of the application will be to enable the Company, through Biocannabix, to secure the appropriate legal authorizations to be able to distribute and sell medical cannabis products in Canada and service other jurisdictions in the export market.
Aurelio Useche, CEO of Relevium stated: “Our core business is health and wellness and the legal Cannabis derivative business is growing exponentially in our niche. In the US, relaxing regulations and a fragmented market place represent a true opportunity to build elevated and trusted cannabinoid derivative consumer brands”. Mr. Useche continued: “In the industrial hemp derivatives space there is rapid proliferation of cannabinoids-based products like CBG and CBD. The challenge, however, is Branding, Quality and Customer Experience, all areas that RLV intends to leverage through its channel expertise.”
The Company’s strategic direction is very much in-line with its core business, which includes the creation of a portfolio of online, direct to consumer retail brands in Health and Wellness, both organically, through licensing agreements and via acquisitions.
The Company understands this is a fast-evolving regulatory environment. In order ensure the adoption of a full legal and compliant framework, the Company is assembling a team of legal and business experts from the space.
About the Market
According to a report from Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is expected to reach $63.5 billion in 2024, growing at a compound annual growth rate of 21.1 percent during the forecast years. North America accounts for over 49% of the market, with the U.S. being the single largest market.
A Major segment of the legal cannabis industry is the hemp-derived cannabidiol (CBD) market. According to a report by Forbes, Brightfield Group projects that Hemp-derived cannabidiol (CBD) will be a billion-dollar market in just three years. CBD products do not have any psychotropic effects and are usually used for medical purposes. Brightfield’s data estimates that hemp CBD sales have already hit $170 million in 2016 and at a 55% compound annual growth rate over the next five years the market will cross the billion-dollar mark. According to Statista, it is estimated that in the year 2020 CBD consumer sales will total around 1.15 billion U.S. dollars. Brightfield determined that 64.5% of the sales come through the online channel followed by 17.8% from physical points of sale.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Targets 83 Million Unique Monthly Visitors and 26 Countries Through European Expansion of Bioganix(R)
Momentum Public Relations
Press Release: April 5 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce that it has started the process of establishing European presence for the new Bioganix® brand in partnership with several online partners, including Amazon. Management will be doing an initial launch of eight best selling products, which will be live online on the week of the May 21, 2018 with full marketing launch by mid summer.
Highlights
- Bioganix® has started European expansion with online partners, including Amazon
- Initial launch of eight best selling products the week of May 21, 2018
Impact on the Business
- Presence in Europe adds 83M monthly unique visitors, over 200M new customers and access to 26 European Countries
- Increased competitive advantage and insulation from seasonality in sales
- Building the “trusted” Bioganix® brand equity internationally to a loyal consumer base
Impact on Shareholders
- Management is investing in growing its main retail asset internationally to deliver sustainable value to customers and shareholders alike
- Exposure of RLV to potential European equity investors through its Frankfurt listing
Aurelio Useche, CEO of Relevium, stated: “The decision to expand to Europe was driven by several key indicators including Amazon’s current investment in the region, access to 230M new customers buying online, higher basket sizes and lower competition. We believe the new Bioganix® brand is poised to gain customer acceptance as a “trusted” brand and successful consumer engagement in the European market”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
Relevium Technologies Inc.
+1.888.528.8687
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in Relevium Technologies
Relevium Announces All-Time Record High of Units Sales for Bioganix(R) in March
Momentum Public Relations
Press Release: April 3 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to report an all-time record high in unit sales for the month of March 2018.
The reported record high of 16,549 units, which was achieved in a seasonally low period, reflects increased online demand for the Bioganix® established product line, which is expected to translate into sales in excess of $439,000 for the month of March. The monthly high did not include the effect from new product launches, which are expected to have an incremental positive impact over the next six months.
The company’s all-time record high of units sold is an important achievement for Relevium’s Bioganix®brand. The Company continues to increase its subscriber base and number of SKUs, now totaling over 230,000 and 38 respectively.
Impact on the Business
- Increase of Bioganix® demand sets the stage for successful launch of new products
- The results indicate that the company’s investment in Mach 2.0 Marketing Engine is starting to pay dividends
Impact on Shareholders
- Increased confidence that management remains engaged on delivering sustainable value to its brands, customers and shareholders
- Incremental value to the acquired Bioganix® business through increased brand equity, exclusive product lines and geographic expansion
- Relevium is steadily building solid base for shareholder value creation, which will deliver future dividends
Abis Hussain, SMO of Relevium, stated: “The implications of this may seem trivial, but the results form this month in a seasonally low period indicate that Mach 2.0 is working as designed. We expect this to also have a positive impact on new products launches over the next six months.”
Aurelio Useche, CEO of Relevium, stated: “This is the first real test of the capabilities of our marketing engine following months of adjustments and beta testing. This small but important success is an important achievement for the company and for our digital marketing and operating teams.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Relevium Launches New Bioganix Brand Architecture
Momentum Public Relations
Press Release March 29 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce it has completed the re-positioning of its Bioganix brand. The new re-positioning enhances Bioganix around the key branding points of Credibility, Quality and Trust. The Company will be rolling out its new brand and new packaging immediately.
The Company is also launching its new website in the first week of April and all new product launches will adopt the guidelines of the new brand architecture that lays out a roadmap to our continued and future success.
Highlights
- Relevium launches new Bioganix brand
- The elevated brand will be catered around Credibility, Quality and Trust
- New Bioganix website launched first week of April
Impact on the Business
- Key differentiation in a very competitive market
- Elevated new brand with premium and exclusive products
- Increased brand equity and recognition
Impact on Shareholders
- Incremental value to the Bioganix assets
- Higher brand recognition = Increased public company awareness
- Steady building of shareholder value for future dividends
Aurelio Useche, CEO of Relevium, stated: “Our team has been working diligently over the last couple of months to launch the newly designed, more recognizable and elevated Bioganix brand,” Mr. Useche stated further: “We are positioning the brand as a recognizable and trusted source of goodness.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
- Published in Relevium Technologies
DIAGNOS Announces the Opening of a Screening Clinic at Chaparral’s Health Management Wellness Center for Medicare Beneficiaries
Momentum Public Relations
Press Release: March 14 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the opening of a third eye screening clinic in California located at Chaparral Medical Group Health Management Wellness Center.
In 2010, Medicare launched an annual benefit to all their members at Chaparral’s Health Management Wellness Center. The goal is to help promote preventive care methods, emphasizing on how to prevent disease instead of treating disease. With that, Chaparral Medical Group has decided it will automatically include eye screening using our CARA platform for diabetic and pre-diabetic patient at their annual visit.
“Chaparral is introducing AI to enhance the overall value of the annual health examination to Medicare members by encompassing CARA as an additional screening test for the annual wellness program. It is estimated that Medicare currently has 44 million beneficiaries enrolled in the Medicare program, some 15 percent of U.S. population. Having Chaparral Medical Group as a trusted partner will help to deploy faster while meeting all the industry requirements,” said Yves-Stephane Couture, VP sales at DIAGNOS.
“By adding eye screening with retina anomalies detection, we are broadening our study for annual wellness visits. As DIAGNOS continues to develop new algorithms and detect more illness, it will significantly help us to prevent disease evolution and take early action. We are proud to use DIAGNOS’ state of the art technology and to benefit from the Artificial Intelligence in our daily fight against diseases and we look forward to using them at the Health Management Centre,” said Dr. Jeereddi Prasad MD, Diabetes Specialist, President, and Medical Director of Chaparral Medical Group.
About Chaparral Medical Group
Chaparral Medical Group is a 80 physicians multi-specialty group serving the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on our FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Daniel Renaud or Thomas Renaud, Managing Directors |
DIAGNOS Inc. | Arrowhead Business and Investment Decisions, LLC |
Tel: 450-678-8882 ext. 224 | Tel: +1 212 619 6889, ext. 7010 |
alarente@diagnos.ca | diagnos@arrowheadbid.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
- 1
- 2